Hypoxia regulates proliferation of acute myeloid leukemia and sensitivity against chemotherapy

Leukemia Research

Volumn 39, Issue 7, 2015, Pages 779-785

  Drolle, Heidrun ^a   Wagner, Michaela ^a   Vasold, Jochen ^a   Kütt, Alexander ^a   Deniffel, Christian ^a   Sotlar, Karl ^a   Sironi, Silvia ^a   Herold, Tobias ^a   Rieger, Christina ^a   Fiegl, Michael ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Acute myeloid leukemia; Bone marrow; Cell cycle; Chemotherapy; Hypoxia

Indexed keywords

CYTARABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P27; VASCULOTROPIN; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MOLECULAR MECHANICS; MYELOID LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; VERY ELDERLY; WESTERN BLOTTING; CELL HYPOXIA; LEUKEMIA, MYELOID, ACUTE; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CELL HYPOXIA; HUMANS; LEUKEMIA, MYELOID, ACUTE;

EID: 84930382597     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.04.019     Document Type: Article

References (24)

1. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013, 368(May (22)):2059-2074.
2. Kottaridis P.D., Gale R.E., Frew M.E., Harrison G., Langabeer S.E., Belton A.A., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98(September (6)):1752-1759.
3. Dohner H., Estey E.H., Amadori S., Appelbaum F.R., Buchner T., Burnett A.K., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115(January (3)):453-474.
4. Schnittger S., Schoch C., Dugas M., Kern W., Staib P., Wuchter C., et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002, 100(July (1)):59-66.
5. Serve H., Krug U., Wagner R., Sauerland M.C., Heinecke A., Brunnberg U., et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol 2013, 31(September (25)):3110-3118.
6. Samudio I., Harmancey R., Fiegl M., Kantarjian H., Konopleva M., Korchin B., et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Investig 2010, 120(January (1)):142-156.
7. Konopleva M., Konoplev S., Hu W., Zaritskey A.Y., Afanasiev B.V., Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 2002, 16(September (9)):1713-1724.
8. Abdel-Wahab O., Levine R.L. Metabolism and the leukemic stem cell. J Exp Med 2010, 207(April (4)):677-680.
9. Parmar K., Mauch P., Vergilio J.A., Sackstein R., Down J.D. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci U S A 2007, 104(March (13)):5431-5436.
10. Fiegl M., Samudio I., Clise-Dwyer K., Burks J.K., Mnjoyan Z., Andreeff M. CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood 2009, 113(February (7)):1504-1512.
11. Sotlar K., Horny H.P., Simonitsch I., Krokowski M., Aichberger K.J., Mayerhofer M., et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004, 28(October (10)):1319-1325.
12. Herold T., Metzeler K.H., Vosberg S., Hartmann L., Rollig C., Stolzel F., et al. Isolated trisomy 13 defines a genetically homogenous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis. Blood 2014, 12(June).
13. Li Z., Herold T., He C., Valk P.J., Chen P., Jurinovic V., et al. Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol 2013, 31(March (9)):1172-1181.
14. Buchner T., Berdel W.E., Schoch C., Haferlach T., Serve H.L., Kienast J., et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006, 24(June (16)):2480-2489.
15. Deeb G., Vaughan M.M., McInnis I., Ford L.A., Sait S.N., Starostik P., et al. Hypoxia-inducible factor-1alpha protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leuk Res 2011, 35(5):579-584.
16. Fiegl M., Spiekermann K. Hypoxia and expression of hypoxia-related proteins in acute myeloid leukemia. Leuk Res 2011, 35(5):573-574.
17. Velasco-Hernandez T., Hyrenius-Wittsten A., Rehn M., Bryder D., Cammenga J. HIF-1alpha can act as a tumor suppressor gene in murine acute myeloid leukemia. Blood 2014, 124(December (24)):3597-3607.
18. Harrison J.S., Rameshwar P., Chang V., Bandari P. Oxygen saturation in the bone marrow of healthy volunteers. Blood 2002, 99(January (1)):394.
19. Suda T., Takubo K., Semenza G.L. Metabolic regulation of hematopoietic stem cells in the hypoxic niche. Cell Stem Cell 2011, 9(October (4)):298-310.
20. Fiegl M., Samudio I., Mnjoyan Z., Korchin B., Fritsche H., Andreeff M. Physiological hypoxia promotes lipid raft and PI3K-dependent activation of MAPK 42/44 in leukemia cells. Leukemia 2010, 24(July (7)):1364-1367.
21. Lloyd R.V., Erickson L.A., Jin L., Kulig E., Qian X., Cheville J.C., et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999, 154(2):313-323.
22. Braess J., Voss S., Jahns-Streubel G., Schoch C., Haferlach T., Kern W., et al. The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity. Br J Haematol 2000, 110(July (1)):170-179.
23. Lowenberg B., van Putten W., Theobald M., Gmur J., Verdonck L., Sonneveld P., et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003, 349(August (8)):743-752.
24. Jin L., Tabe Y., Kojima K., Shikami M., Benito J., Ruvolo V., et al. PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment. J Mol Med 2013, 91(December (12)):1383-1397.